- Home
- KPTI vs ORMP Comparison
KPTI vs ORMP Comparison
Compare KPTI & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- ORMP
- Stock Information
- Founded
- KPTI 2008
- ORMP 2002
- Country
- KPTI United States
- ORMP United States
- Employees
- KPTI N/A
- ORMP N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- ORMP Biotechnology: Pharmaceutical Preparations
- Sector
- KPTI Health Care
- ORMP Health Care
- Exchange
- KPTI Nasdaq
- ORMP Nasdaq
- Market Cap
- KPTI 90.7M
- ORMP 90.7M
- IPO Year
- KPTI 2013
- ORMP N/A
- Fundamental
- Price
- KPTI $0.62
- ORMP $2.18
- Analyst Decision
- KPTI Strong Buy
- ORMP Hold
- Analyst Count
- KPTI 4
- ORMP 1
- Target Price
- KPTI $5.00
- ORMP N/A
- AVG Volume (30 Days)
- KPTI 676.1K
- ORMP 114.8K
- Earning Date
- KPTI 02-27-2025
- ORMP 03-05-2025
- Dividend Yield
- KPTI N/A
- ORMP N/A
- EPS Growth
- KPTI N/A
- ORMP N/A
- EPS
- KPTI N/A
- ORMP 0.11
- Revenue
- KPTI $148,442,000.00
- ORMP N/A
- Revenue This Year
- KPTI $5.47
- ORMP N/A
- Revenue Next Year
- KPTI $6.33
- ORMP N/A
- P/E Ratio
- KPTI N/A
- ORMP $19.96
- Revenue Growth
- KPTI 1.77
- ORMP N/A
- 52 Week Low
- KPTI $0.58
- ORMP $2.00
- 52 Week High
- KPTI $1.95
- ORMP $3.67
- Technical
- Relative Strength Index (RSI)
- KPTI 40.06
- ORMP 32.21
- Support Level
- KPTI $0.65
- ORMP $2.18
- Resistance Level
- KPTI $0.70
- ORMP $2.27
- Average True Range (ATR)
- KPTI 0.05
- ORMP 0.07
- MACD
- KPTI -0.00
- ORMP -0.01
- Stochastic Oscillator
- KPTI 11.00
- ORMP 13.79
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.